ARTICLE | Company News
Roivant launches respiratory vant, announces other vant news
September 21, 2018 5:36 PM UTC
Roivant Sciences GmbH (Basel, Switzerland) announced the launch of a new respiratory disease subsidiary, a real-world evidence partnership between its Datavant Inc. (San Francisco, Calif.) subsidiary and CRO Parexel International Corp. (Waltham, Mass.), and its Urovant Sciences Ltd. (Basel, Switzerland) urology subsidiary setting terms for its IPO. Roivant has established 13 drug development subsidiaries which it calls "vants."
Newly formed Respivant Sciences acquired its sole candidate, RVT-1601 (PA101), this month from Patara Pharma Inc. (San Diego, Calif.). Patara ceased operations following the acquisition, and Patara CEO Bill Gerhart will serve as CEO for the Roivant subsidiary...